Evidence map›Paper›PMID 36999409›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2023

A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial.

Giuseppe Tarantini, Peter Cornelius Smits, Thibault Lhermusier, Benjamin Honton, Grégoire Rangé, Christophe Piot, Gilles Lemesle, Juan Miguel Ruiz Nodar, Matthieu Godin, Maria Madera Cambero and 5 more

2 registry-linked trialsOpen access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04753749 nacompletednot on this map

Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

TypeinterventionalSponsorMicroPort CRMRan2021 to 2025Enrolled2,248ConditionsMyocardial Infarction, Acute, Coronary Artery DiseaseArmsShortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT
NCT07644234 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke

TypeinterventionalSponsorSichuan Provincial People's HospitalRan2026 to 2029Enrolled3,836ConditionsIschemic Stroke, Transient Ischemic AttackArmsClopidogrel, Aspirin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Giuseppe TarantiniDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Peter Cornelius SmitsMaasstad Ziekenhuis, Rotterdam, the Netherlands.
Thibault LhermusierCHU de Toulouse, Pôle Cardiovasculaire et Métabolique, Toulouse, France.
Benjamin HontonDepartment of Interventional Cardiology, Clinique Pasteur, Toulouse, France.
Grégoire RangéService de Cardiologie, Centre Hospitalier de Chartres, Hôpital Louis Pasteur, Le Coudray, France.
Christophe PiotService/Pôle de Cardiologie, Clinique du Millénaire, Montpellier, France.
Gilles LemesleHeart and Lung Institute, University Hospital of Lille, Lille, France.
Juan Miguel Ruiz NodarServicio de Cardiologia, Hospital General Universitario de Alicante, Alicante, Spain.
Matthieu GodinService Cardiologie, Clinique Saint Hilaire, Rouen, France.
Maria Madera CamberoTergooi MC, Blaricum, the Netherlands.
Pascal MotreffService/Pôle Cardiologie, Hôpital Gabriel-Montpied, Clermont-Ferrand, France.
Thomas CuissetService de Cardiologie, University Hospital La Timone, Marseille, France.
David BouchezMicroPort CRM, Clinical Affairs, Clamart, France.
Yann PoezevaraMicroPort CRM, Clinical Affairs, Clamart, France.
Guillaume CaylaService de Cardiologie, CHU de Nîmes, Université de Montpellier, Nîmes, France.
Centre Hospitalier Universitaire de Toulouse · FRClinique Pasteur · FRLes Hôpitaux de Chartres · FRLille’s Cardiology Hospital · FRMaasstad Ziekenhuis · NLUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the latest knowledge and technological advancements, it is still debatable whether a modern revascularisation approach in the setting of acute myocardial infarction (AMI), including complete revascularisation (in patients with significant non-culprit lesions) with newer-generation highly biocompatible drug-eluting stents, requires prolonged dual antiplatelet therapy (DAPT). TARGET-FIRST (ClinicalTrials.gov: NCT04753749) is a prospective, open-label, multicentre, randomised controlled study comparing short (one month) DAPT versus standard (12 months) DAPT in a population of patients with non-ST/ST-segment elevation myocardial infarction, completely revascularised at index or staged procedure (within 7 days), using Firehawk, an abluminal in-groove biodegradable polymer rapamycin-eluting stent. The study will be conducted at approximately 50 sites in Europe. After a mandatory 30-40 days of DAPT with aspirin and P2Y

Indexed as

Drug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionEquivalence Trials as TopicHumansMulticenter Studies as TopicPlatelet Aggregation InhibitorsPolymersProspective StudiesRandomized Controlled Trials as TopicSirolimusTreatment OutcomePlatelet Aggregation InhibitorsPolymersSirolimus

Identifiers

PMID36999409
PMCPMC11064808
OpenAlexW4362458210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.